Genzyme Sells Pharma Intermediates Business to ICIG

Biotechnology company Genzyme (Cambridge, MA) says it has completed the sale of its pharmaceutical intermediates business to the International Chemical Investors Group (ICIG; Frankfurt). Financial terms of the deal were not disclosed. ICIG purchased all of the pharmaceutical intermediates business, excluding the drug delivery technologies unit. The acquired business has been renamed Corden Pharma Switzerland and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma group. The Corden Pharma group is the pharmaceutical market...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers